Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$23.38 USD

23.38
91,149

+0.04 (0.17%)

Updated Nov 5, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid

by Zacks Equity Research

Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako and broad product portfolio. However, pricing pressure raises a concern.

Veeva Systems (VEEV) Inks Deal to Advance Clinical Trials

by Zacks Equity Research

Veeva Systems (VEEV) collaborates with Parexel to accelerate clinical trials by combining the best of each company's experience.

Here's Why You Should Hold on to LabCorp (LH) Stock Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.

Urmimala Biswas headshot

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

by Urmimala Biswas

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

Medtronic (MDT) Boosts Diabetes Management via New Infusion Set

by Zacks Equity Research

Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.

Trina Mukherjee headshot

Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch

by Trina Mukherjee

Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.

XRAY vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

Bruker Corporation (BRKR) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

Bruker's (BRKR) revenue improvement in the first quarter is likely to have been boosted by robust performance by all three of its BSI groups.

PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services

by Zacks Equity Research

PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.

Reasons to Hold on to Align Technology (ALGN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on solid customer adoption of Invisalign and iTero products.

Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B

by Zacks Equity Research

Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.

Here's Why You Should Add Phibro (PAHC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Phibro (PAHC), owing to its potential in Performance Products and consistent high demand for its nutritional specialty products.

Globus Medical (GMED) Hurt by Dull Global Growth, Low Margins

by Zacks Equity Research

Pricing continues to remain a major headwind for Globus Medical (GMED).

Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman

by Zacks Equity Research

Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.

Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up

by Zacks Equity Research

Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.

Here's Why You Should Hold on to Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.

Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions

by Zacks Equity Research

Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.

Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market

by Zacks Equity Research

Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.

Integra's (IART) Neurosurgery Rebounds Despite Supply Issues

by Zacks Equity Research

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,

Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit

by Zacks Equity Research

According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.

Surging Earnings Estimates Signal Upside for Dentsply (XRAY) Stock

by Zacks Equity Research

Dentsply (XRAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why You Should Add DENTSPLY SIRONA (XRAY) to Your Portfolio

by Zacks Equity Research

Investor confidence is high in the DENTSPLY SIRONA (XRAY) stock, thanks to solid prospects.